GKWIM
MDNA

Gerber Kawasaki Wealth & Investment Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed -$1K – 1204
2021
Q3 		$1K Buy
+1
New +$2 ﹤0.01% 1140

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's MDNA Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2021, closing a stake of 1 share — an estimated $1K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in MDNA in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 23 funds tracked by Wall St. Rank hold MDNA as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 1 Medicenna Therapeutics Corp. Common Shares share in Q4 2021, an estimated $1K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Medicenna Therapeutics Corp. Common Shares position peaked at $1K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.